908 Devices Inc.

908 Devices Inc.

908 Devices Inc. is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. Its devices are used at the point-of-need to interrogate unknown and invisible materials and provide actionable answers to directly address some of the critical problems in forensics, bioprocessing, pharma/biopharma, life science research and adjacent markets. Its forensics & field detection products include MX908, XplorIR, ProtectIR, ThreatID, and InterceptIR. MX908 is a handheld, battery-powered, Mass Spec device designed for the analysis of solid, liquid, vapor and aerosol materials of unknown identity. MX908 is a multi-purpose device utilized by a spectrum of user segments for a variety of forensic field applications, including chemical, explosive, priority drug and hazardous materials operations, detecting materials at the trace level. XplorIR is a handheld gas detector that can detect and quantify unknown chemicals and vapors in seconds.

Stock Performance Snapshot

Strong Buy

Analyst Rating

Analysts highly recommend purchasing 908 Devices' stock, expecting it to rise in value.

Above Average

Financial Health

908 Devices is performing well with strong revenue and cash flow, indicating good financial stability.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring MASS

Wearable Tech IP Wars: What Investors Should Know

Wearable Tech IP Wars: What Investors Should Know

Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.

Published: August 21, 2025

Explore Basket
Pharma's American Reshoring Wave

Pharma's American Reshoring Wave

AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.

Published: July 23, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Growth through innovation

New compact mass‑spec and microfluidic platforms could open markets beyond traditional labs, though commercial adoption and execution risk remain.

Product‑led revenue

High‑value instruments paired with consumables and service can create recurring income, but scaling sales and support is resource‑intensive.

🌍

Diverse end markets

Applications span pharma, forensics and environment, offering diversification; demand can vary with research budgets and regulatory cycles.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

TMO

Thermo Fisher Scientific, Inc.

Thermo Fisher provides a range of services and products that help customers advance their research, solve complex analytical challenges, improve patient diagnostics, and increase laboratory productivity.

ISRG

Intuitive Surgical, Inc.

A healthcare company that develops, manufactures, and markets robotic-assisted surgical systems for procedures in multiple specialties

Frequently asked questions